Logo image of ALLK

ALLAKOS INC (ALLK) Stock Fundamental Analysis

NASDAQ:ALLK - Nasdaq - US01671P1003 - Common Stock - Currency: USD

0.3291  0 (-0.06%)

After market: 0.3285 0 (-0.18%)

Fundamental Rating

2

Taking everything into account, ALLK scores 2 out of 10 in our fundamental rating. ALLK was compared to 551 industry peers in the Biotechnology industry. While ALLK seems to be doing ok healthwise, there are quite some concerns on its profitability. ALLK does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ALLK has reported negative net income.
ALLK had a negative operating cash flow in the past year.
In the past 5 years ALLK always reported negative net income.
ALLK had a negative operating cash flow in each of the past 5 years.
ALLK Yearly Net Income VS EBIT VS OCF VS FCFALLK Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100M -200M -300M

1.2 Ratios

ALLK's Return On Assets of -119.89% is on the low side compared to the rest of the industry. ALLK is outperformed by 80.43% of its industry peers.
Looking at the Return On Equity, with a value of -146.95%, ALLK is doing worse than 62.46% of the companies in the same industry.
Industry RankSector Rank
ROA -119.89%
ROE -146.95%
ROIC N/A
ROA(3y)-92.97%
ROA(5y)-70.14%
ROE(3y)-120.01%
ROE(5y)-88.81%
ROIC(3y)N/A
ROIC(5y)N/A
ALLK Yearly ROA, ROE, ROICALLK Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200 -250

1.3 Margins

ALLK does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALLK Yearly Profit, Operating, Gross MarginsALLK Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

6

2. Health

2.1 Basic Checks

ALLK has more shares outstanding than it did 1 year ago.
The number of shares outstanding for ALLK has been increased compared to 5 years ago.
ALLK has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ALLK Yearly Shares OutstandingALLK Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
ALLK Yearly Total Debt VS Total AssetsALLK Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

Based on the Altman-Z score of -20.10, we must say that ALLK is in the distress zone and has some risk of bankruptcy.
ALLK has a worse Altman-Z score (-20.10) than 84.70% of its industry peers.
ALLK has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -20.1
ROIC/WACCN/A
WACCN/A
ALLK Yearly LT Debt VS Equity VS FCFALLK Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M

2.3 Liquidity

A Current Ratio of 4.81 indicates that ALLK has no problem at all paying its short term obligations.
The Current ratio of ALLK (4.81) is comparable to the rest of the industry.
A Quick Ratio of 4.81 indicates that ALLK has no problem at all paying its short term obligations.
With a Quick ratio value of 4.81, ALLK perfoms like the industry average, outperforming 53.74% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.81
Quick Ratio 4.81
ALLK Yearly Current Assets VS Current LiabilitesALLK Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 67.35% over the past year.
EPS 1Y (TTM)67.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%64.2%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 12.03% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y52.97%
EPS Next 2Y35.1%
EPS Next 3Y23.51%
EPS Next 5Y12.03%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ALLK Yearly Revenue VS EstimatesALLK Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2029 2030 2031 2032 50M 100M 150M 200M
ALLK Yearly EPS VS EstimatesALLK Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -1 -2 -3 -4 -5

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ALLK. In the last year negative earnings were reported.
Also next year ALLK is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALLK Price Earnings VS Forward Price EarningsALLK Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALLK Per share dataALLK EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1

4.3 Compensation for Growth

A more expensive valuation may be justified as ALLK's earnings are expected to grow with 23.51% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.1%
EPS Next 3Y23.51%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ALLK!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ALLAKOS INC

NASDAQ:ALLK (5/14/2025, 8:18:43 PM)

After market: 0.3285 0 (-0.18%)

0.3291

0 (-0.06%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-07 2025-05-07/amc
Earnings (Next)08-05 2025-08-05/amc
Inst Owners95.4%
Inst Owner Change-8.58%
Ins Owners1.39%
Ins Owner Change-1566.35%
Market Cap29.74M
Analysts50
Price Target1.26 (282.86%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)58.61%
Min EPS beat(2)17.22%
Max EPS beat(2)100%
EPS beat(4)3
Avg EPS beat(4)14.71%
Min EPS beat(4)-69.86%
Max EPS beat(4)100%
EPS beat(8)5
Avg EPS beat(8)2.19%
EPS beat(12)7
Avg EPS beat(12)-1.63%
EPS beat(16)8
Avg EPS beat(16)-4.05%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)20.32%
PT rev (3m)40.15%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-0.73%
EPS NY rev (1m)0%
EPS NY rev (3m)-2.26%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.38
P/tB 0.38
EV/EBITDA N/A
EPS(TTM)-0.8
EYN/A
EPS(NY)-0.23
Fwd EYN/A
FCF(TTM)-1.04
FCFYN/A
OCF(TTM)-1.04
OCFYN/A
SpS0
BVpS0.87
TBVpS0.87
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -119.89%
ROE -146.95%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-92.97%
ROA(5y)-70.14%
ROE(3y)-120.01%
ROE(5y)-88.81%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1.54%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.81
Quick Ratio 4.81
Altman-Z -20.1
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)43%
Cap/Depr(5y)321.55%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)67.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%64.2%
EPS Next Y52.97%
EPS Next 2Y35.1%
EPS Next 3Y23.51%
EPS Next 5Y12.03%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y39.43%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year58.23%
EBIT Next 3Y39.36%
EBIT Next 5YN/A
FCF growth 1Y19.93%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y19.62%
OCF growth 3YN/A
OCF growth 5YN/A